PIK3CA MUTATION
Clinical trials for PIK3CA MUTATION explained in plain language.
Never miss a new study
Get alerted when new PIK3CA MUTATION trials appear
Sign up with your email to follow new studies for PIK3CA MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check the drug's safety, find the right dose, and se…
Matched conditions: PIK3CA MUTATION
Phase: PHASE1 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated May 16, 2026 22:26 UTC
-
New drug targets root cause of rare overgrowth diseases in kids and adults
Disease control Recruiting nowThis study tests a new drug, RLY-2608, designed to block a faulty protein that causes abnormal growth in people with PIK3CA-related overgrowth spectrum (PROS) and related malformations. The trial enrolls 277 adults and children to see if the drug can safely shrink overgrown tissu…
Matched conditions: PIK3CA MUTATION
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for hard-to-treat breast cancer: targeted combo enters phase 3
Disease control Recruiting nowThis study tests whether a new drug (RLY-2608) combined with fulvestrant works better than another approved combination (capivasertib + fulvestrant) for people with advanced or metastatic HR+/HER2- breast cancer that has a PIK3CA mutation. About 540 adults whose cancer worsened a…
Matched conditions: PIK3CA MUTATION
Phase: PHASE3 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New drug targets Hard-to-Treat cancers with specific gene mutation
Disease control Recruiting nowThis early-stage study tests a new drug, RLY-2608, designed to block a faulty protein in cancer cells with a specific gene change (PIK3CA mutation). It is for adults with advanced solid tumors or certain breast cancers that have not responded to other treatments. The study will t…
Matched conditions: PIK3CA MUTATION
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:20 UTC